This work is licensed under the Creative Commons Attribution 4.0 International License.
Kashiwagi T, Okada Y, Nomoto K. Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan. Paediatr Drugs. 2018;20(1):97-104. doi: 10.1007/s40272-017-0264-y. Erratum in: Kashiwagi T, Okada Y, Nomoto K. Correction to: Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan. Paediatr Drugs. 2018;20(3):291. doi: 10.1007/s40272-018-0291-3KashiwagiTOkadaYNomotoKPalivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in JapanPaediatr Drugs201820197104doi10.1007/s40272-017-0264-y.Erratum in: Kashiwagi T, Okada Y, Nomoto K. Correction to: Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan. Paediatr Drugs. 2018;20(3):291. doi: 10.1007/s40272-018-0291-3Open DOISearch in Google Scholar
Roglić S. Infekcije djece respiratornim sincicijskim virusom. Respiratory syncytial virus infection in children. Paediatr Croat. 2018; 62 (Supl 1): 236-41. (XXXV. Seminar Hrvatske proljetne pedijatrijske škole u Splitu od 16. do 20. 04. 2018)RoglićSInfekcije djece respiratornim sincicijskim virusom. Respiratory syncytial virus infection in childrenPaediatr Croat201862Supl 123641XXXV. Seminar Hrvatske proljetne pedijatrijske škole u Splitu od 16. do 20. 04. 2018Search in Google Scholar
Mori M, Kawashima H, Nakamura H, Nakagawa M, Kusuda S, Saji T, et al.; Surveillance Committee for Severe RSV Infection. Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan. J Infect Chemother. 2011;17(2):254-63. doi: 10.1007/s10156-010-0121-1MoriMKawashimaHNakamuraHNakagawaMKusudaSSajiTet alSurveillance Committee for Severe RSV Infection. Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in JapanJ Infect Chemother201117225463doi10.1007/s10156-010-0121-1Open DOISearch in Google Scholar
Feltes TF, Sondheimer HM, Tulloh RM, Harris BS, Jensen KM, Losonsky GA, et al.; Motavizumab Cardiac Study Group. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res. 2011;70(2):186-91. doi: 10.1203/PDR.0b013e318220a553FeltesTFSondheimerHMTullohRMHarrisBSJensenKMLosonskyGAet alMotavizumab Cardiac Study Group. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart diseasePediatr Res201170218691doi10.1203/PDR.0b013e318220a553Open DOISearch in Google Scholar
Beckhaus AA, Castro-Rodriguez JA. Down Syndrome and the Risk of Severe RSV Infection: A Meta-analysis. Pediatrics. 2018;142(3):e20180225. doi: 10.1542/peds.2018-0225BeckhausAACastro-RodriguezJADown Syndrome and the Risk of Severe RSV Infection: A Meta-analysisPediatrics20181423e20180225doi10.1542/peds.2018-0225Open DOISearch in Google Scholar
Mori M, Onodera M, Morimoto A, Kosaka Y, Morio T, Notario GF, et al. Palivizumab use in Japanese infants and children with immunocompromised conditions. Pediatr Infect Dis J. 2014;33(11):1183-5. doi: 10.1097/INF.0000000000000392MoriMOnoderaMMorimotoAKosakaYMorioTNotarioGFet alPalivizumab use in Japanese infants and children with immunocompromised conditionsPediatr Infect Dis J2014331111835doi10.1097/INF.0000000000000392Open DOISearch in Google Scholar
Committee on Infectious Diseases: collaborators: Bocchini Jr JA, Bernstein HH, Bradley JS, Brady MT, Byington CL, Fisher MC, et al. From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694-701. doi: 10.1542/peds.2009-2345Committee on Infectious Diseases: collaboratorsBocchini JrJABernsteinHHBradleyJSBradyMTByingtonCLFisherMCet alFrom the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infectionsPediatrics200912461694701doi10.1542/peds.2009-2345Open DOISearch in Google Scholar
Gutfraind A, Galvani AP, Meyers LA. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection. JAMA Pediatr. 2015;169(4):341-8. doi: 10.1001/jama-pediatrics.2014.3804GutfraindAGalvaniAPMeyersLAEfficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infectionJAMA Pediatr201516943418doi10.1001/jama-pediatrics.2014.3804Open DOISearch in Google Scholar
Sánchez Luna M, Pérez Muñuzuri A, Leante Castellanos JL, Ruiz Campillo CW, Sanz López E, Benavente Fernández I, et al.; en representación de la Comisión de Estándares de la Sociedad Española de Neonatología. Recomendaciones de la Sociedad Española de Neonatología para la utilización de palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial en lactantes de alto riesgo, actualización. [An update of the recommendations of the Spanish Neonatology Society for the use of palivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high risk infants]. An Pediatr (Engl Ed). 2019;91(5):348-50. Spanish. doi: 10.1016/j.anpedi.2019.08.003SánchezLuna MPérezMuñuzuri ALeanteCastellanos JLRuizCampillo CWSanzLópez EBenaventeFernández Iet alen representación de la Comisión de Estándares de la Sociedad Española de Neonatología. Recomendaciones de la Sociedad Española de Neonatología para la utilización de palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial en lactantes de alto riesgo, actualización. [An update of the recommendations of the Spanish Neonatology Society for the use of palivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high risk infants]An Pediatr (Engl Ed)201991534850Spanishdoi10.1016/j.anpedi.2019.08.003Open DOISearch in Google Scholar
American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):415-20. doi: 10.1542/peds.2014-1665. Erratum in: Pediatrics. 2014;134(6):1221American Academy of Pediatrics Committee on Infectious DiseasesAmerican Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infectionPediatrics2014134241520doi10.1542/peds.2014-1665.Erratum in: Pediatrics. 2014;134(6):1221Open DOISearch in Google Scholar
Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545-55. doi: 10.1016/S0140-6736(10)60206-1NairHNokesDJGessnerBDDheraniMMadhiSASingletonRJet alGlobal burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysisLancet20103759725154555doi10.1016/S0140-6736(10)60206-1Open DOISearch in Google Scholar
Bacharier LB, Cohen R, Schweiger T, Yin-Declue H, Christie C, Zheng J, et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2012;130(1):91-100.e3. doi: 10.1016/j.jaci.2012.02.010BacharierLBCohenRSchweigerTYin-DeclueHChristieCZhengJet alDeterminants of asthma after severe respiratory syncytial virus bronchiolitisJ Allergy Clin Immunol2012130191100e3doi10.1016/j.jaci.2012.02.010Open DOISearch in Google Scholar
Gupta P, Beam BW, Rettiganti M. Temporal Trends of Respiratory Syncytial Virus-Associated Hospital and ICU Admissions Across the United States. Pediatr Crit Care Med. 2016;17(8):e343-51. doi: 10.1097/PCC.0000000000000850GuptaPBeamBWRettigantiMTemporal Trends of Respiratory Syncytial Virus-Associated Hospital and ICU Admissions Across the United StatesPediatr Crit Care Med2016178e34351doi10.1097/PCC.0000000000000850Open DOISearch in Google Scholar
Mori M, Watabe S, Taguchi T, Hasegawa H, Ishige M, Tanuma N, et al. Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection. BMC Pediatr. 2021;21(1):106. doi: 10.1186/s12887-021-02567-6MoriMWatabeSTaguchiTHasegawaHIshigeMTanumaNet alStudy protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infectionBMC Pediatr2021211106doi10.1186/s12887-021-02567-6Open DOISearch in Google Scholar
Mahadevia PJ, Masaquel AS, Polak MJ, Weiner LB. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective. J Med Econ. 2012;15(5):987-96. doi: 10.3111/13696998.2012.690013MahadeviaPJMasaquelASPolakMJWeinerLBCost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspectiveJ Med Econ201215598796doi10.3111/13696998.2012.690013Open DOISearch in Google Scholar
Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M; Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol. 2008;28(7):511-7. doi: 10.1038/jp.2008.28FrogelMNerwenCCohenAVanVeldhuisenPHarringtonMBoronMPalivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes RegistryJ Perinatol20082875117doi10.1038/jp.2008.28Open DOISearch in Google Scholar
Kamori A, Morooka Y, Yamamura K, Chong PF, Kuga N, Takahata Y, et al. Effect of delayed palivizumab administration on respiratory syncytial virus infection-related hospitalisation: A retrospective, observational study. Medicine (Baltimore). 2021;100(47):e27952. doi: 10.1097/MD.0000000000027952KamoriAMorookaYYamamuraKChongPFKugaNTakahataYet alEffect of delayed palivizumab administration on respiratory syncytial virus infection-related hospitalisation: A retrospective, observational studyMedicine (Baltimore)202110047e27952doi10.1097/MD.0000000000027952Open DOISearch in Google Scholar
Yamagami H, Kimura H, Hashimoto T, Kusakawa I, Kusuda S. Detection of the Onset of the Epidemic Period of Respiratory Syncytial Virus Infection in Japan. Front Public Health. 2019;7:39. doi: 10.3389/fpubh.2019.00039YamagamiHKimuraHHashimotoTKusakawaIKusudaSDetection of the Onset of the Epidemic Period of Respiratory Syncytial Virus Infection in JapanFront Public Health2019739doi10.3389/fpubh.2019.00039Open DOISearch in Google Scholar
Oliveira DB, Iwane MK, Prill MM, Weinberg GA, Williams JV, Griffin MR, et al. Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis. J Clin Virol. 2015;65:26-31. doi: 10.1016/j.jcv.2015.01.016OliveiraDBIwaneMKPrillMMWeinbergGAWilliamsJVGriffinMRet alMolecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxisJ Clin Virol2015652631doi10.1016/j.jcv.2015.01.016Open DOISearch in Google Scholar
Viguria N, Navascués A, Juanbeltz R, Echeverría A, Ezpeleta C, Castilla J. Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children. Hum Vaccin Immunother. 2021;17(6):1867-72. doi: 10.1080/21645515.2020.1843336ViguriaNNavascuésAJuanbeltzREcheverríaAEzpeletaCCastillaJEffectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk childrenHum Vaccin Immunother2021176186772doi10.1080/21645515.2020.1843336Open DOISearch in Google Scholar